How is Evomela used?
Evomela™ (melphalan, Spectrum Pharmaceuticals) is an intravenous chemotherapy drug approved for use in the United States for the treatment of multiple myeloma in two groups of patients:
- Patients receiving high-dose chemotherapy in preparation for an autologous stem cell transplant (ASCT)
- Patients who are receiving melphalan as palliative treatment mainly for symptom and pain relief and cannot take oral melphalan
What types of patients can benefit from Evomela?
Evomela has been shown to be effective as high-dose chemotherapy when given prior to ASCT in transplant-eligible patients with myeloma.
Evomela has also been shown to be bioequivalent, or similar to conventional intravenous melphalan in how it is available in the body after it has been administered. For this reason, it can be used in the same manner as conventional melphalan in combination with prednisone for the treatment of myeloma.
How does Evomela work?
Evomela is a reformulated version of the drug melphalan (Alkeran®). Melphalan is a chemotherapy agent that belongs to a class of agents referred to as alkylating agents. Alkylating agents are used to treat cancer because they damage the DNA in cancer cells and cause them to die. Intravenous melphalan is the most common type of high-dose chemotherapy used in preparation for ASCT in patients with myeloma.
Evomela differs from conventional melphalan in how it is prepared for administration into a vein (intravenously). Once it is prepared, it is stable at room temperature for a longer period of time than conventional melphalan. In addition, unlike conventional melphalan, prepared Evomela can be refrigerated and is stable for 24 hours at refrigerated temperatures. These properties may result in improved convenience in administration. They may also allow for slower infusion rates and/or longer times for administration, which may also improve patients’ ability to receive their full intended dosing of Evomela.